Coblopasvir

Coblopasvir

Coblopasvir is an antiviral drug used in the treatment of hepatitis C. It is a direct-acting antiviral (DAA) that targets the NS5A protein of the hepatitis C virus (HCV), inhibiting its replication. Coblopasvir is often used in combination with other antiviral medications to enhance its efficacy and reduce the likelihood of resistance.

Mechanism of Action

Coblopasvir works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. By blocking this protein, coblopasvir prevents the virus from multiplying and spreading within the host's body. This action helps to reduce the viral load and allows the immune system to clear the infection more effectively.

Clinical Use

Coblopasvir is typically prescribed as part of a combination therapy for the treatment of chronic hepatitis C infection. It is effective against multiple genotypes of the virus, making it a versatile option for patients with different strains of HCV. The drug is usually administered orally and is taken once daily.

Side Effects

Common side effects of coblopasvir include fatigue, headache, and nausea. In some cases, patients may experience more severe side effects such as anemia or liver enzyme abnormalities. It is important for patients to be monitored regularly by their healthcare provider while taking coblopasvir to manage any potential adverse effects.

Drug Interactions

Coblopasvir can interact with other medications, potentially altering their effectiveness or increasing the risk of side effects. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid harmful interactions.

Related Pages

• Hepatitis C
• Antiviral drug
• Direct-acting antiviral
• NS5A protein
• Viral replication

See Also

• Sofosbuvir
• Ledipasvir
• Velpatasvir
• Glecaprevir

‎